<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01107782</url>
  </required_header>
  <id_info>
    <org_study_id>87-821</org_study_id>
    <nct_id>NCT01107782</nct_id>
  </id_info>
  <brief_title>Sildenafil and Uteroplacental Perfusion</brief_title>
  <official_title>Phase 2 Study of Fetal Growth Retardation Treatment by Sildenafil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether sildenafil is effective and safe in the
      treatment of fetal growth restriction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fetal growth retardation affects up to 8% of all pregnancies and has massive short term
      (increased fetal morbidity and mortality) and long-term (increased incidence of
      cardiovascular disorders in adulthood) health implications.

      Doppler waveform analysis of these pregnancies suggests compromised uteroplacental
      circulation and placental hypoperfusion.

      Our aim is to assess if sildenafil citrate could improve vasodilatation in FGR pregnancies.

      Sildenafil citrate may offer a potential therapeutic strategy to improve uteroplacental
      perfusion in FGR.

      Animal studies suggest that phosphodiesterase-5 (PDE5) inhibitors, such as sildenafil
      citrate, may improve uterine blood flow .
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">January 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Uteroplacental Perfusion</measure>
    <time_frame>2 hours after sildenafil ingestion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>fetal growth</measure>
    <time_frame>after 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>umbilical artery blood gass assessment</measure>
    <time_frame>immediately after birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effect on fetal well being</measure>
    <time_frame>2 hours after sildenafil</time_frame>
    <description>when BP score is&lt;8 we repeat it after sildenafil ingestion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Fetal Growth Retardation</condition>
  <arm_group>
    <arm_group_label>sildenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil</intervention_name>
    <description>50 mg TDS orally until birth</description>
    <arm_group_label>sildenafil</arm_group_label>
    <other_name>viagra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>50mg tid</description>
    <arm_group_label>Placebo control</arm_group_label>
    <other_name>placebo tid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  FGR pregnancies in 24-37 weeks of GA

        Exclusion Criteria:

          -  vasodilator agents usage

          -  history of cardiovascular morbidity specially of right heart side

          -  drug or alcohol abusers

          -  systolic BP more than 210 mm Hg or diastolic BP more than 120 mm Hg
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>marzieh vahid dastjerdi, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Iranian's ministery of health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sayedeh Afagh Hosseini, MD.</last_name>
    <role>Study Director</role>
    <affiliation>resident of OB&amp;GYN</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>sayedeh afagh hosseini, M.D.</last_name>
    <phone>+989188111670</phone>
    <email>afahoss@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tehran UMS</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>sayedeh afagh hosseini, M.D.</last_name>
      <phone>+989188111670</phone>
      <email>afahoss@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Marzieh Vahid Dastjerdi, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sayedeh Afagh Hosseini, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2010</study_first_submitted>
  <study_first_submitted_qc>April 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2010</study_first_posted>
  <last_update_submitted>February 22, 2011</last_update_submitted>
  <last_update_submitted_qc>February 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Marzieh Vahid Dastjerdi</name_title>
    <organization>Tehran University of Medical Sciences</organization>
  </responsible_party>
  <keyword>sildenafil</keyword>
  <keyword>FGR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

